



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Agar-entrapped sulfonated DABCO: Agelly acidic catalyst for the acceleration of one-pot synthesis of 1,2,4-triazoloquinazolinone and some pyrimidine derivatives

Issa Mousazadeh Moghaddampour^a, Farhad Shirini^{a,*},
Mohaddeseh Safarpour Nikoo Langarudi^b

^a Department of Chemistry, College of Science, University of Guilan, University Campus 2, Rasht, Iran

^b Department of Chemistry, College of Science, University of Guilan, Rasht, 41335-19141, Iran

ARTICLE INFO

Article history:

Received 12 July 2020

Revised 15 September 2020

Accepted 24 September 2020

Available online 26 September 2020

Keyword:

DABCO

Agar-entrapped catalyst

Ionic liquids (ILs)

Triazole

Uracile

Quinazolinone

Green chemistry

Gel-entrapped acidic catalyst (GEACs)

ABSTRACT

In this project, a recently synthesized DABCO-based catalyst is entrapped in agar to reduce its moisture sensitivity leading to enhancement of its stability and catalytic activity. After preparation and identification this new reagent is used as an efficient and environmentally safe catalyst for the preparation of 1, 2, 4-triazoloquinazolinone and some pyrimidine derivatives. This method is accompanied with some superiorities such as, simple operation, mild and green conditions, use of low cost and non-hazardous natural material, short reaction times, easy preparation methods and simple work-up procedures. The prepared catalyst can be re-used for several times in all of the studied reactions without any appreciable loss in its activity.

© 2020 Elsevier B.V. All rights reserved.

1. Introduction

Agar is a hydrophilic, colloidal substance consisting of the polysaccharides extracted from *Gelidium cartilagineum* Gaillon, *Gracilaria confervoides* Greville, and related red algae [1], probably existing in the form of its calcium salt or a mixture of calcium and magnesium salts. It is a complex mixture of polysaccharides composed of two major fractions agarose, a neutral polymer, and agarpectin, a charged, sulfated polymer. Agarose, the gelling fraction, is a neutral linear molecule essentially free of sulfates, consisting of chains of repeating alternate units of β -1,3-linked *D*-galactose and α -1,4-linked 3,6-anhydro-*L*-galactose. Agarpectin, the non-gelling fraction, is a sulfated polysaccharide (3% to 10% sulfate), composed of agarose and varying percentages of ester sulfate, *D*-glucuronic acid, and small amounts of pyruvic acid. Agarose normally represents at least two-thirds of the natural agar (Fig. 1).

Because of their special structural characteristics, triazoles are considered as important class of heterocyclic compounds show-

ing interesting biological, pharmaceutical and therapeutic activities including antifungal [2], antimicrobial [3–8], anti-cancer [9], anti-convulsant [10], antihypertensive [11], and anti-viral [12]. In this regard many drugs containing triazole moiety are manufactured, which of them Ribavirin or Copegus (an antiviral), Alprazolam (an anxiolytic), Letrozole (an anticancer), and Flusilazole (an organosilicon fungicide) [13] are examples (Fig. 2a).

Uracil, as one of the four nucleobases in the nucleic acid, is a common and naturally occurring pyrimidine derivative. In RNA uracil binds to adenine *via* two hydrogen bonds, and in DNA the uracil nucleobase is replaced by *thymine*. This considerable interest is correlated with a huge range of biological activities such as, antitumor [14], antifolate [15], antihypertensive [16], and cardio tonic (may be prescribed when the heart is not pumping enough blood to supply other organs) [17]. A number of popular drugs including the uracil moiety are Sofosbuvir (a new antiviral for COVID-19) [18], Uramustine (a chemotropic drug that damage DNA) [19] and Uridine monophosphate (a nucleotide that is used as a monomer in RNA) [20] (Fig. 2b). Recently the remedial effect in COVID-19 (human coronavirus) patients was also observed that it has been proven by Ribavirin [21].

In recent years, a gel-entrapped-base catalysts (GEBs), which in them the advantages of alkali and organic bases with those

* Corresponding author.

E-mail addresses: shirini@guilan.ac.ir, fshirini@gmail.com (F. Shirini).




Fig. 1. Agar/agarose structure and agar-entrapped sulfonated DABCO.




Fig. 2. The structures of some triazole (a) and uracil (b) containing drugs.

of heterogeneous supports are combined with each other is going to become an attractive concept for organic chemists. In this line, Salunkhe and co-workers reported the preparation of agar-agar entrapped-DABCO and its applicability in the promotion of the synthesis of 2-amino-4*H*-chromenes [22]. This strategy causes to reduce the amounts of the base used in the reactions and ease of the product isolation, along with making a cut in moisture absorption by the catalyst [23].

Recently we have reported the preparation of [DABCO] (SO₃H)₂(Cl)₂ as an acidic IL and its use in the acceleration of some of the multi-component reactions [24], although the method is useful but its ability in the adsorption of moisture causes that its efficiency to be reduced. For this reason we motivated to use the above mentioned strategy to prepare, a gel entrapped acidic ionic liquid (GEAIL) by the entrapping of this reagent in agar for the first time. After identification the effect of this method on the mois-

ture adsorption and catalytic ability of this reagent is studied in the synthesis of some triazole and uracil containing derivatives as an example.

2. Experimental

2.1. Materials and instruments

All solvents and materials, employed in this study, were purchased from Aldrich (Mumbai) and Merck Chemical Companies (Munich) and utilized without any further purification. Solvents were stored in airtight containers and had been distilled before being applied. To ensure about the purity of materials, they were checked with thin layer chromatography (TLC) on silica-gel polygram SILG/UV 254 plates and their melting points were compared with authenticated melting points in Merck and Aldrich indexes.




Fig. 3. Agar in heated water (a), [DABCO](SO₃H)₂(Cl)₂ (b), ionic liquid in warm water (c) and agar-entrapped ionic liquid (d).

Melting points were determined by electro-thermal IA9100 melting point apparatus in capillary tubes. The melting point range was input manually through keyboard and the material changes were visually monitored. FT-IR spectra were recorded on a Perkin-Elmer spectrum BX series with KBr plates for solid samples. ¹H NMR and ¹³C NMR spectra were recorded on Bruker AV-400 and -500 using TMS (0.00 ppm) as internal standard and DMSO-*d*₆ as the solvent.

2.2. Preparation of [DABCO](SO₃H)₂(Cl)₂

The acidic ionic liquid was precisely prepared according to the reported procedure in the article [24].

2.3. Preparation of agar-entrapped IL

In a 150 mL flask, 5.0 g agar in 50 mL water was heated at boiling point to be completely dissolved (Fig. 3-a). Then a solution of 2.5 g of [DABCO](SO₃H)₂(Cl)₂ (7.2 mmol, Fig. 3-b), in warm water (50 mL) (Fig. 3-c), was added into preceding solution and stirred for 10 min. After that, the flask was poured into a petri dish and dried in vacuum oven for 12 h to obtain agar-entrapped IL as rough brown crystals (Fig. 3-d).

2.4. General procedure for the preparation of 1,2,4-triazoloquinazolinones

To a mixture of aromatic aldehyde 1 (1 mmol), 3-amino-1,2,4-triazole 2 (1 mmol), and β-diketone (dimedone 3, methyl acetoacetate 4 or 1,3-cyclohexadione 5) (1 mmol), agar-entrapped catalyst (0.03 g for 6, 0.02 g for 7 and 8) was added in a 25 mL round-bottom flask. Then the mixture was stirred magnetically in the absence of solvent in an oil bath (100 °C) for the appropriate time. The reaction process was carefully monitored by TLC (*n*-hexane: ethyl acetate; 8:3). After completion of the reaction, 5 mL water was poured into the reaction medium and filtered off to separate the catalyst. Finally, the obtained precipitate was recrystallized from ethanol to afford the required product (6a-j, 7a-f, and 8a-g). The spectral data of new compounds are as follow:




Fig. 4. Hydrogen bond probability of agar-entrapped IL.

Diethyl-7,7'-(butane-1,4-diyl-bis(oxy))bis(4,1-phenylene))bis(5-methyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate) (7e)

IR (KBr, ν/cm^{-1}): 3422, 3135, 2934, 2871, 1692, 1642, 1581, 1510, 1473, 1427, 1383, 1248; ¹H NMR (500 MHz, DMSO-*d*₆), δ = 1.04 (t, *J* = 7.1 Hz, 3H, CH₃), 1.80 (br, 2H, CH₂), 2.41 (s, 3H, CH₃), 3.98 – 3.91 (m, 4H, 2CH₂), 6.21 (s, 1H, CH), 6.83 (d, *J* = 8.6 Hz, 2H, 2CH), 7.11 (d, *J* = 8.6 Hz, 2H, 2CH), 7.63 (s, 1H, CH), 10.76 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆), δ = 14.3, 18.8, 25.7, 59.3, 59.7, 67.5, 114.6, 115.3, 128.6, 132.2, 146.8, 147.3, 150.4, 158.6, 165.6.

Diethyl-7,7'-(hexane-1,6-diyl-bis(oxy))bis(4,1-phenylene))bis(5-methyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate) (7f)

IR (KBr, ν/cm^{-1}): 3381, 3097, 2987, 2867, 1695, 1653, 1591, 1510, 1489, 1415, 1370, 1266; ¹H NMR (500 MHz, DMSO-*d*₆), δ = 1.03 (t, *J* = 7.5 Hz, 3H, CH₃), 1.43 (br, 2H, CH₂), 1.67 (br, 2H, CH₂), 2.40 (s, 3H, CH₃), 3.93 – 4.05 (m, 4H, 2CH₂), 6.20 (s, 1H, CH), 6.82 (d, *J* = 8.0 Hz, 2H, 2CH), 7.10 (d, *J* = 7.8 Hz, 2H, 2CH), 7.63 (s, 1H, CH), 10.76 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆), δ = 14.3, 18.8, 25.7, 29.0, 59.3, 59.7, 67.7, 114.5, 115.3, 128.6, 132.2, 146.8, 147.3, 150.4, 158.7, 165.6.

9-(2-Nitrophenyl)-5,6,7,9-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-8(4H)-one (8d)

IR (KBr, ν/cm^{-1}) 3444, 3213, 2910, 1643, 1569, 1357; ¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm) 1.88–1.99 (2H, m, CH₂), 2.17–2.27 (2H, m, CH₂), 2.64–2.67 (2H, m, CH₂), 6.98 (1H, s, CH), 7.30 (1H, d, *J* = 1.2 Hz, CH-Ph), 7.49 (1H, dt, *J*₁ = 7.6 Hz, *J*₂ = 0.8 Hz, CH-Ph), 7.61 (1H, dt, *J*₁ = 7.6 Hz, *J*₂ = 1.2 Hz, CH-Ph), 7.73 (1H, s, CH-triazole), 7.86 (1H, dd, *J*₁ = 8 Hz, *J*₂ = 1.2 Hz, CH-Ph), 11.32 (1H, s, NH); ¹³C NMR (100 MHz, DMSO-*d*₆): δ (ppm) 21.1, 26.8, 36.4, 53.4, 106.19, 124.4, 129.4, 129.8, 133.8, 135.3, 147.2, 149.0, 150.8, 153.7, 193.9.

9,9'-(Butane-1,4-diylbis(oxy))bis(4,1-phenylene))bis(5,6,7,9-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-8(4H)-one) (8f)

IR (KBr, ν/cm^{-1}): 3422, 3230, 2926, 2833, 1644, 1584, 1511, 1476, 1416, 1362, 1250; ¹H NMR (500 MHz, DMSO-*d*₆), δ = 1.79 (s, 2H, CH₂), 2.05 – 1.83 (m, 2H, CH₂), 2.30 – 2.20 (m, 2H, CH₂), 2.70 – 2.58 (m, 2H, CH₂), 3.94 (t, *J* = 5.2 Hz, 2H, CH₂), 6.17 (s, 1H, CH), 6.81 (d, *J* = 8.4 Hz, 2H, 2CH), 7.10 (d, *J* = 8.3 Hz, 2H, 2CH), 7.67 (s, 1H, CH), 11.11 (s, 1H, NH); ¹³C NMR (125 MHz, DMSO-*d*₆),




Fig. 5. FT-IR spectra of DABCO (a), [DABCO] (SO_3H) $_2\text{Cl}_2$ (b), agar (c) and agar-entrapped IL (d).




Fig. 6. SEM of DABCO (a and b) and agar-entrapped IL (c and d).




Fig. 7. TGA diagrams of agar (a) IL (b) and agar-entrapped IL (c).




Fig. 8. A comparison between moisture resistant property of agar, IL, and agar-entrapped IL.

$\delta = 21.1, 25.8, 26.8, 36.8, 57.5, 67.5, 114.5, 115.3, 128.6, 134.1, 147.1, 150.3, 152.7, 158.5, 193.7.$

9,9'-(Hexane-1,6-diylbis(oxy)bis(4,1-phenylene))bis(5,6,7,9-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-8(4H)-one) (8 g)

IR (KBr, ν/cm^{-1}): 3423, 3229, 2931, 2868, 1648, 1581, 1511, 1474, 1414, 1360, 1246; $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$), $\delta = 1.41$ (br, 2H, CH_2), 1.67 (br, 2H, CH_2), 1.98 – 1.86 (m, 2H, CH_2), 2.29 – 2.20 (m, 2H, CH_2), 2.69 – 2.58 (m, 2H, CH_2), 3.89 (t, $J = 6.7$ Hz, 2H, CH_2), 6.16 (s, 1H, CH), 6.80 (d, $J = 8.2$ Hz, 2H, 2CH), 7.09

(d, $J = 8.1$ Hz, 2H, 2CH), 7.66 (s, 1H, CH), 11.10 (s, 1H, NH); $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$), $\delta = 21.1, 25.7, 26.8, 29.0, 36.8, 57.5, 67.7, 114.5, 115.3, 128.5, 134.0, 147.1, 150.3, 152.7, 158.6, 193.7.$

2.5. General procedure for the preparation of 1, 2, 4-triazolo[4,3-a]pyrimidines

To a mixture of aromatic aldehyde 1 (1 mmol), 3-amino-1,2,4-triazole 2 (1 mmol), and malononitrile 9 (1 mmol), in a 25 mL round-bottom flask, agar-entrapped catalyst (0.02 g) was added. Then the mixture was stirred magnetically under solvent-free conditions in an oil bath (100 °C) for the appropriate time. The progress of the reaction was carefully monitored by TLC (*n*-hexane: ethyl acetate; 4:1). After completion of the reaction, 5 mL water was poured into the reaction medium and then filtered off to separate the catalyst. Finally, the obtained precipitate was recrystallized from ethanol to afford the required product (10a-f).

5-amino-7-(naphthalen-2-yl)-7,8-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carbonitrile (10f)

M.p. 281–282 °C; IR (KBr, ν, cm^{-1}) 3360, 3256, 3183, 2189, 1657, 1629, 1526; $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$): 5.56 (d, $J = 2$ Hz, 1H, CH), 7.31 (d, $J = 2.8$ Hz, 2H, NH_2), 7.50–7.55 (m, 3H, CH-Ph), 7.77 (d, $J = 10.8$ Hz, 2H, CH-Ph), 7.90–7.97 (m, 3H, $\text{N}=\text{CH}-\text{N}$ and CH-Ph), 8.88 (d, $J = 2.4$ Hz, 1H, NH); $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO}-d_6$): 54.3, 119.0, 124.4, 124.6, 126.2, 126.5, 127.5, 127.6, 127.9, 128.7, 132.5, 132.6, 140.3, 147.0, 151.9, 153.9.





Fig. 9. Reusability of the catalyst in the synthesis of 1,2,4-triazoloquinazolinones (6b, 7a, 8b), 1,2,4-triazolo[4,3-a]pyrimidines (10b), pyrido[4,5-b]quinolone (12b) and pyrido[2,3-d]pyrimidines (13b).



Scheme 1. Synthesis of 1,2,4-triazolo[4,3-a]pyrimidine, pyrido[2,3-d]pyrimidine and pyrido[4,5-b]pyrimidine, and 1,2,4-triazoloquinazolinone derivatives.

2.6. General procedure for the preparation of pyrido[4,5-b]quinolone

To a mixture of aromatic aldehyde **1** (1 mmol), 6-amino-1,3-dimethyluracil **11** (1 mmol), dimedone **3** (1 mmol) in a 25 mL round-bottom flask, 0.02 g agar-entrapped catalyst was added and 5 mL of ethanol/water (2:1) was poured on it. The mixture was stirred magnetically to dissolve all components at reflux temperature. The reaction process was carefully checked by TLC (*n*-hexane: ethyl acetate; 4: 1). After completion, the mixture was filtered off to separate the catalyst, which is solvated in the solvent. Recrystallization of the product from absolute ethanol led to the pure product (**12a-h**).

2.7. General procedure for the preparation of pyrido[2,3-d]pyrimidines

Into a 25 mL round-bottom flask containing aldehyde **1** (1 mmol), 6-amino-1,3-dimethyluracil **11** (1 mmol), and malononitrile


9 (1 mmol), 5 mL ethanol and 0.03 g agar-entrapped catalyst were added. The mixture was stirred magnetically at 70 °C to dissolve all components. The precipitate of the product is appeared in the reaction medium after a short time. The reaction progress was traced to completion by TLC (*n*-hexane: ethyl acetate; 1: 4). After completion of the reaction, the mixture was filtered off and the obtained residue was washed with water to remove the catalyst. Finally, the crude product was recrystallized from ethanol if necessary (**13a-i**).

3. Results and discussion

3.1. Characterization of the catalyst

3.1.1. Fourier-Transform infrared spectroscopy (FT-IR)

When a molecule is entrapped in a linear polysaccharide through hydrogen bonding, it can be expected that the number and intensity of the peaks of its functional groups be decreases due



Scheme 2. The hypothesized mechanism for the synthesis of 1,2,4-triazolo[4,3-*a*]pyrimidine, pyrido[2,3-*d*]pyrimidine and pyrido[4,5-*b*]pyrimidine, and 1,2,4-triazoloquinazolinone derivatives in the presence of agar-entrapped IL.

to a lock in the structure (Fig. 4). This phenomena can be seen by the comparison of the FT-IR spectra of free IL and agar-entrapped IL (Fig. 5).

3.1.2. Scanning electron microscopy (SEM)

As shown in Fig. 6, the morphology of DABCO changed going through the entrapping process. However, DABCO has porous and irregular shape with tiny holes, it change to an aggregated particles due to hydrogen bonding between hydroxyl groups of IL and agar.

3.1.3. Thermal gravimetric analysis (TGA)

TGA diagrams of agar, IL, and agar-entrapped IL are represented at Fig. 7. As shown, the major weight loss from agar-entrapped IL are happened between 369 and 681 °C (44.3%) which is related to decomposition of the catalyst. Before that, the weight loss (28.89%) between 219 and 312 °C is attributed to the thermal decomposition of IL which is entrapped in agar. The weight loss from the catalyst between 62 and 157 °C is owing to the decomposition of agar and the removal of physically adsorbed water and organic solvents, which were used in creating the catalyst.

3.2. Moisture-resistant property

In spite of great features of ionic liquids such as non-flammability, no miscibility with non-polar solvents, and negligible vapor pressure, these compounds are very sensitive on exposure to air and moisture. Moisture adsorption can be impacted on the properties of ILs; for example, can lead to a cut in the thermal stability or catalytic activity. For this reason, finding a protocol which increases the moisture resistance can be thoroughly vital.

In order to show the effect of agar-trapping on the moisture adsorption of the selected IL, we carried out loss on drying test for

agar, IL, and agar-entrapped IL using Karl-Fischer method in 4 steps during 36 h at a standard temperature (23 °C) and 63% relative humidity in the laboratory.

The obtained results show an acceptable decrease in the amount of the moisture which can be observed by IL after its entrapping in agar (Fig. 8). As shown, the moisture adsorption decreased when the IL trapped in agar. It can be related to an increase in the H-bonding of catalyst with agar, as shown in Fig. 4, which cause to a cut in the positions which can H-bond with water [25].

3.3. Catalytic activity

After ensuring about the preparation of the catalyst, the catalytic activity of the entrapped IL was investigated in the synthesis of 1,2,4-triazolo[4,3-*a*]pyrimidine, pyrido[2,3-*d*]pyrimidine, pyrido[4,5-*b*]pyrimidine and 1,2,4-triazoloquinazolinone derivatives.

At first, to gain the best conditions for the reactions, the synthesis of 4-chlorobenzaldehyde derivatives of these types of compounds (6b, 8b, 10b, 12b, 13b) was investigated as models for all reactions. In the case of compounds 7a-f the optimization studies were done on benzaldehyde as a selected model. The results are collected in Table 1. As shown, different amounts of catalyst and various conditions were used to optimize the reaction conditions in accuracy. Which is distinguished in the table, agar-entrapped IL is more effective when thermal conditions and protic solvents were used (7a, 8b, 12b, and 13b). However, this catalyst was able to accelerate the synthesis of 6b and 10b in the absence of solvent. On the basis of the obtained results the best conditions are determined as shown in Scheme 1.

Table 1
Optimization of the reaction conditions for the synthesis of **6b** (entries 1–10), **7a** (entries 11–18), **8b** (entries 19–26), **10b** (entries 27–35), **12b** (entries 36–44), **13b** (entries 45–52).

Entry	Catalyst amount (g)	Solvent	Temp. (°C)	Time (min.)	Conversion (Isolated yield%)
1	0.01	MeCN	r.t.	120	NR ^a
2	0.03	MeCN	Reflux	120	NR ^a
3	0.01	CH ₂ Cl ₂	r.t.	120	NR ^a
4	0.03	CH ₂ Cl ₂	Reflux	120	NR ^a
5	0.03	H ₂ O	Reflux	120	NC ^b
6	0.03	EtOH/H ₂ O	Reflux	120	NC ^b
7	0.03	EtOH	Reflux	120	NC ^b
8	0.01	–	100	120	100 (70)
9	0.02	–	100	90	100 (90)
10	0.03	–	100	60	100 (91)
11	0.20	H ₂ O	r.t.	100	Not NC ^b
12	0.20	MeCN	Reflux	60	NR ^a
13	0.20	MeCN	Reflux	60	NR ^a
14	0.20	CH ₂ Cl ₂	Reflux	60	NR ^a
15	0.20	CH ₂ Cl ₂	Reflux	30	NR ^a
16	0.20	H ₂ O	100	30	100 (90)
17	0.10	EtOH/H ₂ O	100	60	100 (70)
18	0.20	EtOH	100	30	100 (95)
19	0.20	H ₂ O	r.t.	100	NC ^b
20	0.20	MeCN	Reflux	60	NR ^a
21	0.20	MeCN	Reflux	60	NR ^a
22	0.20	CH ₂ Cl ₂	Reflux	60	NR ^a
23	0.20	CH ₂ Cl ₂	Reflux	30	NR ^a
24	0.20	H ₂ O	100	30	100 (90)
25	0.10	EtOH/H ₂ O	100	60	100 (70)
26	0.20	EtOH	100	20	100 (95)
27	0.01	MeCN	r.t.	75	NR ^a
28	0.01	MeCN	Reflux	90	NR ^a
29	0.01	EtOH	Reflux	90	Trace
30	0.01	H ₂ O	Reflux	90	Trace
31	0.01	EtOH/H ₂ O	r.t.	90	NC ^b
32	0.01	EtOH/H ₂ O	Reflux	90	NC ^b
33	0.01	–	100	90	100 (90)
34	0.01	–	100	40	100 (90)
35	0.02	–	100	35	100 (98)
36	0.02	MeCN	r.t.	120	NR ^a
37	0.03	MeCN	Reflux	120	NR ^a
38	0.02	CH ₂ Cl ₂	r.t.	120	NC ^b
39	0.03	CH ₂ Cl ₂	Reflux	120	NC ^b
40	0.03	H ₂ O	r.t.	120	NC ^b
41	0.03	EtOH	Reflux	120	100 (70)
42	0.02	EtOH/H ₂ O	Reflux	100	100 (80)
43	0.03	EtOH/H ₂ O (2:1)	Reflux	75	100 (91)
44	0.02	EtOH/H₂O (2:1)	Reflux	75	100 (92)
45	0.03	MeCN	r.t.	120	NC ^b
46	0.03	MeCN	Reflux	120	NC ^b
47	0.03	H ₂ O	Reflux	120	NC ^b
48	0.03	EtOH/H ₂ O	Reflux	120	NC ^b
49	0.03	EtOH/H ₂ O (2:1)	Reflux	120	NC ^b
50	0.03	EtOH	Reflux	40	100 (80)
51	0.04	EtOH	Reflux	40	100 (80)
52	0.03	EtOH	Reflux	55	100 (97)

^a No reaction.

^b Not completed.

After optimization of the reaction conditions, we have developed our studies by utilization of miscellaneous aldehydes with withdrawal and/or donor functional groups. The obtained outcomes were collected in Table 2. These results show that under the selected conditions the requested products can be obtained in high yields during acceptable reaction times with no considerable effect of the substituents on the aromatic ring. Because that, in spite of the aromatic aldehydes, a mixture of unidentified products were formed when aliphatic aldehydes were employed, the related results were not included in Table 2. In this study some new triazole derivatives are prepared from bis-aldehydes which their results are highlighted in Table 2.

The mechanism starts from activation of aldehyde **1** via catalyst through H-bonding (intermediate **a**). After that, the route divides to two pathways. In route 1, activated 1,3-diketone (enol **b**) makes for intermediate **a** comes to **c** after loss water. If 3-amino-1,2,4-triazole **2** reacts with **c** through N² or N³H₂, the obtained products can be different. If N² attacks to **c**, the products **6a-j**, **7a-f**, and **8a-g** produce after intra-molecular cyclization (intermediate **d**) and tautomerization. If intermediate **c** is attacked with N³H₂, intermediate **e** produces which led to product **A**. But if it happened, aliphatic –CH in ring, assigned with red circle, should be split as a doublet with *J* = 2 Hz. This peak appeared as a singlet in the ¹H NMR spectra of **6 h**, **7e**, **7f**, **8f**, and **8 g** which approves 3-amino-1,2,4-triazole

Table 2

Preparation of 1,2,4-triazolo quinazolinone (entries 1–23), 1,2,4-triazolo[4,3-*a*] pyrimidines (entries 24–29), pyrido[4,5-*b*]quinolone (entries 30–37) and pyrido[2,3-*d*]pyrimidines (entries 38–46) in the presence of agar-entrapped acidic IL as the catalyst.

Entry	Ar	Subs.	Subs.	Pro.	Time (min.)	Yield (%) ^a	Melting point (°C)	
							Found	Rep. [Ref.]
1	C ₆ H ₅ -	triazole	DM ^b	6a	95	94	248–249	248–250 [26]
2	4-ClC ₆ H ₄ -	triazole	DM ^b	6b	60	91	300–302	303–305 [27]
3	2-MeOC ₆ H ₄ -	triazole	DM ^b	6c	85	97	299–300	298–300 [28]
4	4-OHC ₆ H ₄ -	triazole	DM ^b	6d	90	95	>300	>300 [29]
5	2-Naphtaldehyde	triazole	DM ^b	6e	80	95	289–292	287–290 [29]
6	4-NO ₃ C ₆ H ₄ -	triazole	DM ^b	6f	90	96	285–287	284–286 [26]
7	3-NO ₃ C ₆ H ₄ -	triazole	DM ^b	6 g	100	94	268–269	266–269 [29]
8	2-NO ₃ C ₆ H ₄ -	triazole	DM ^b	6h	110	94	292–294	290–292 [30]
9	4-MeOC ₆ H ₄ -	triazole	DM ^b	6i	115	98	224–227	222–224 [26]
10	3-MeOC ₆ H ₄ -	triazole	DM ^b	6j	110	95	>300	>300 [31]
11	C ₆ H ₅ -	triazole	MAA ^c	7a	30	95	193–194	193–194 [32]
12	4-MeOC ₆ H ₄ -	triazole	MAA ^c	7b	60	90	233–234	233–235 [32]
13	4-NO ₃ C ₆ H ₄ -	triazole	MAA ^c	7c	45	90	257–258	257–258 [32]
14	4-MeC ₆ H ₄ -	triazole	MAA ^c	7d	60	–	Dec. ^d	– [32]
15	[(CH ₂) ₂ OC ₆ H ₄] ₂ -	triazole	MAA ^c	7e	60	88	>300	New
16	[(CH ₂) ₃ OC ₆ H ₄] ₂ -	triazole	MAA ^c	7f	80	85	>300	New
17	C ₆ H ₅ -	triazole	CH ^e	8a	20	91	299–300	300–301 [31]
18	4-ClC ₆ H ₄ -	triazole	CH ^e	8b	20	95	294–295	294–295 [33]
19	3-NO ₃ C ₆ H ₄ -	triazole	CH ^e	8c	35	84	298–299	299–300 [31]
20	2-NO ₃ C ₆ H ₄ -	triazole	CH ^e	8d	45	86	>300	>300 [34]
21	4-MeOC ₆ H ₄ -	triazole	CH ^e	8e	40	87	>300	>300 [31]
22	[(CH ₂) ₂ OC ₆ H ₄] ₂ -	triazole	CH ^e	8f	60	89	>300	New
23	[(CH ₂) ₃ OC ₆ H ₄] ₂ -	triazole	CH ^e	8 g	65	89	>300	New
24	C ₆ H ₅ -	triazole	MN ^f	10a	30	95	>300	>300 [35]
25	4-ClC ₆ H ₄ -	triazole	MN ^f	10b	35	98	256–257	255–257 [35]
26	2-ClC ₆ H ₄ -	triazole	MN ^f	10c	40	93	264–266	264–265 [35]
27	4-MeOC ₆ H ₄ -	triazole	MN ^f	10d	40	94	220–223	220–221 [35]
28	2-NO ₃ C ₆ H ₄ -	triazole	MN ^f	10e	30	93	247–248	246–247 [35]
29	2-Naphtaldehyde	triazole	MN ^f	10f	50	94	281–282	280–283 [36]
30	C ₆ H ₅ -	uracil	DM ^b	12a	55	92	270–271	269–270 [37]
31	4-ClC ₆ H ₄ -	uracil	DM ^b	12b	75	92	288–289	287–288 [38]
32	4-NO ₃ C ₆ H ₄ -	uracil	DM ^b	12c	105	95	224–226	224–225 [37]
33	3-NO ₃ C ₆ H ₄ -	uracil	DM ^b	12d	110	93	223–224	221–223 [37]
34	2-ClC ₆ H ₄ -	uracil	DM ^b	12e	80	92	>300	>300 [38]
35	2-NO ₃ C ₆ H ₄ -	uracil	DM ^b	12f	110	93	289–290	287–290 [39]
36	4-MeOC ₆ H ₄ -	uracil	DM ^b	12 g	100	93	>300	>300 [38]
37	2-MeOC ₆ H ₄ -	uracil	DM ^b	12h	80	94	>300	>300 [38]
38	C ₆ H ₅ -	uracil	MN ^f	13a	50	93.2	>300	>300 [40]
39	4-ClC ₆ H ₄ -	uracil	MN ^f	13b	55	97	>300	>300 [41]
40	2-ClC ₆ H ₄ -	uracil	MN ^f	13c	60	92	>300	>300 [41]
41	4-MeOC ₆ H ₄ -	uracil	MN ^f	13d	50	94	>300	>300 [40]
42	4-NO ₃ C ₆ H ₄ -	uracil	MN ^f	13e	55	94	>300	>300 [42]
43	2-Naphtaldehyde	uracil	MN ^f	13f	60	94	>300	>300 [43]
44	3-BrC ₆ H ₄ -	uracil	MN ^f	13 g	65	95	>300	>300 [41]
45	3-NO ₃ C ₆ H ₄ -	uracil	MN ^f	13h	60	94	>300	>300 [41]
46	2-NO ₃ C ₆ H ₄ -	uracil	MN ^f	13i	60	95	>300	>300 [42]

^a Isolated yields.

^b Dimedone.

^c Methyl acetoacetate.

^d Decomposition.

^e Cyclohexadione.

^f Malononitrile.

2 participates in reaction through N². On the other hand, owing to the replacement of 3-amino-1,2,4-triazole **2** with 6-amino-1,3-dimethyluracil **11**, the products **12a–h** were produced path through intermediate **f**.

In route 2, malononitrile **9** gets activated by catalyst to attack intermediate **a** and produce **h** as a key intermediate. Then whether 3-amino-1,2,4-triazole **2** or 6-amino-1,3-dimethyluracil **11**, products **10a–f** or **13a–i** can be produced, going through intermediates **i** and **k**, respectively. But, by contrast, to produce product **10a–f**, N³H₂ from 3-amino-1,2,4-triazole **2** should attack **h**, if not, product **B** prepares. The doublet peak about 5.5 ppm with *J* = 2 Hz in the ¹H NMR of **10f** confirmed that the aliphatic –CH and –NH are in the neighborhood (Scheme 2)

A brilliant feature of a catalyst which changes it as a convenient one is its recyclability. For investigation of this feature of our new catalyst, the synthesis of 4-chlorobenzaldehyde derivative in each reaction (6a, 8b, 10b, 12b, and 13b except 7a–f which benzaldehyde was used for the synthesis of 7a) is selected as model. After completion of the reaction and separation of the product the solvent is removed under vacuum at 50 °C. The obtained precipitate was eluted by diethyl ether and used for another reaction. This study showed that the catalyst can be reused at least for 3 consecutive runs without considerable decrease in its activity (Fig. 9).

In order to show the catalytic ability of the prepared reagent, the efficiency of agar-entrapped IL with some of the other catalysts in the synthesis of 5-amino-7-(4-chlorophenyl)-

Table 3

Comparison of the activity of agar-entrapped IL with those of other reported catalysts in the synthesis of 5-amino-7-(4-chlorophenyl)-7,8-dihydro[1,2,4]triazolo[4,3-*a*]pyrimidine (10b, entries 1–6) and 7-amino-5-(4-chlorophenyl)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-*d*]pyrimidine-6-carbonitrile (13b, entries 7–11) compared performance.

Entry	Catalyst/Conditions [Ref.]	Time (min.)	Yield (%)
1	NaOH/Reflux-EtOH [35]	30	82
2	NaOH/US-H ₂ O [35]	60	88
3	1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) / Reflux-EtOH [44]	15	90
4	[H ₂ -DABCO][H ₂ PO ₄] ₂ /Solvent-free, 100 °C [36]	40	95
5	[H ₂ -DABCO][ClO ₄] ₂ /Solvent-free, 100 °C [36]	50	96
6	Agar entrapped [DABCO](SO ₃ H) ₂ Cl ₂ Solvent-free -100 °C	35	98
7	Nano-MgO/H ₂ O, 80 °C [41]	15	90
8	Triethanolamine/H ₂ O, 80 °C [45]	120	92
9	Al-HMS-20/EtOH-r.t. [46]	720	92
10	[H ₂ -DABCO][ClO ₄] ₂ /EtOH, 70 °C [36]	50	95
11	Agar-entrapped [DABCO](SO ₃ H) ₂ Cl ₂ /EtOH, 70 °C	55	97

7,8-dihydro[1,2,4]triazolo[4,3-*a*]pyrimidine and 7-amino-5-(4-chlorophenyl)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-*d*]pyrimidine-6-carbonitrile, is compared in Table 3. This comparison implies that the selected reactions are carried out better using this new catalyst.

4. Conclusions

We have used agar-entrapped [DABCO](SO₃H)₂(Cl)₂ as a novel, highly efficient and green catalyst for the multi-component synthesis of 1,2,4-triazoloquinazolinone, 1,2,4-triazolo [4,3-*a*] pyrimidine, pyrido[4,5-*b*]quinolone and pyrido [2,3-*d*]pyrimidine derivatives. This new catalyst has the least absorption of humidity leading to more stability of the selected acidic ionic liquid. High yields, short reaction times, ease of separation, and stability and reusability of the catalyst are some of the important advantages of the method.

We hope that this newly reported idea can be a useful way for the stabilization of other moisture sensitive reagents leading to their broad range of applications in organic transformations.

Credit author statement

This article introduces agar-entrapped sulfonated DABCO as a gelly acidic catalyst for the acceleration of one-pot synthesis of 1,2,4-triazoloquinazolinone and some pyrimidine derivatives.

The main advantages of this method are: introduction of novel protocols for the synthesis of 1,2,4-triazoloquinazolinone and some pyrimidine derivatives in mild and green conditions. Moreover, using small amounts of non-metal catalysts, high yields of products, no by-product and simple work-up procedures are added advantages of these procedures. It should be emphasized that the submission is original, not under consideration for publication elsewhere, and that all authors are aware of the submission and agree to its publication.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We are thankful to the Research Council of University of Guilan for the partial support of this research.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.molstruc.2020.129336](https://doi.org/10.1016/j.molstruc.2020.129336).

References

- [1] B. Tozkoparan, N. Gokhan, G. Aktay, E. Yesilada, M. Ertan, 6-Benzylidenethiazolo[3,2-*b*]-1,2,4-triazole-5(6*H*)-one substituted with ibuprofen: synthesis, characterization and evaluation of anti-inflammatory activity, *Eur. J. Med. Chem.* 34 (2000) 743–750, doi:10.1016/S0223-5234(00)00157-4.
- [2] J. del Arco, J. Galindo, V.J. Clemente-Surez, A. Corrales, J. Fernandez-Lucas, Sustainable synthesis of uridine-5'-monophosphate analogues by immobilized uracil phosphoribosyltransferase from *Thermus thermophilus*, *BBA-Proteins Proteom.* 1868 (2020) 140251, doi:10.1016/j.bbapap.2019.07.004.
- [3] B.S. Holla, R. Gonsalves, S. Shenoy, Studies on some N-bridged heterocycles derived from bis-[4-amino-5-mercapto-1,2,4-triazol-3-yl] alkanes, *II Farmaco* 53 (1998) 574–578, doi:10.1016/S0014-827X(98)00068-8.
- [4] S. Ersan, S. Nacak, R. Berkem, Synthesis and antimicrobial activity of *N*-[(α -methyl)benzylidene]-(3-substituted-1,2,4-triazol-5-yl-thio)acetohydrazides, *II Farmaco* 53 (1998) 773–776, doi:10.1016/S0014-827X(98)00095-0.
- [5] N. Demirbas, S.A. Karaoglu, A. Demirbas, E. Çelik, Synthesis and antimicrobial activities of some new [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazoles and [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazines, *ARKIVOC* (2005) 75–91, doi:10.3998/ark.5550190.0006.108.
- [6] A.A. Ikizler, F. Ucar, N. Demirbas, I. Yasa, A. Ikizler, T. Genzer, Antimicrobial activities of some 4*H*-1,2,4-triazoles, *Indian J. Pharm. Sci.* 61 (1999) 271–274 <https://www.ijpsonline.com/abstract/antimicrobial-activities-of-some-4h124triazoles-1442.html>.
- [7] N.J.P. Subhashini, E.P. Kumara, N. Gurrappu, V. Yerragunta, Design and synthesis of imidazo-1,2,3-triazoles hybrid compounds by microwave-assisted method: evaluation as an antioxidant and antimicrobial agents and molecular docking studies, *J. Mol. Struct.* 1180 (2019) 618, doi:10.1016/j.molstruc.2018.11.029.
- [8] K. Thotla, V. Noole, K. Reddy, Synthesis and antimicrobial activity of a novel hybrid benzo[*b*]thiophene-1,2,3-triazole analogues, *Chem. Data Collect.* 27 (2020) 100361, doi:10.1016/j.cdc.2020.100361.
- [9] N. Demirbas, A. Demirbas, S.A. Karaoglu, Synthesis and biological activities of new 1,2,4-triazol-3-one derivatives, *Russ. J. Bioorg. Chem.* 31 (2005) 387–397, doi:10.1007/s11171-005-0054-0.
- [10] M. Kritsanida, A. Mouroutsou, P. Marakos, N. Pouli, S. Papakonstantinou-Garoufalas, C. Pannecouque, M. Witvrouw, E. De Clercq, Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazoles, *II Farmaco* 57 (2002) 253–257, doi:10.1016/S0014-827X(01)01189-2.
- [11] A. Alizadeh, Synthesis of some new 1,2,4-triazole derivatives by Mitsunobu chemistry, *Helvetica* 88 (2005) 2777–2780, doi:10.1002/hlca.200590218.
- [12] G. Turan-Zitouni, Z.A. Kaplançikli, K. Erol, F.S. Kilic, Synthesis and analgesic activity of some triazoles and triazolothiadiazines, *II Farmaco* 54 (1999) 218–223, doi:10.1016/S0014-827X(99)00016-6.
- [13] B. Tozkoparan, N. Gokhan, G. Aktay, E. Yesilada, M. Ertan, 6-Benzylidenethiazolo[3,2-*b*]-1,2,4-triazole-5(6*H*)-one substituted with ibuprofen: synthesis, characterization and evaluation of anti-inflammatory activity, *Eur. J. Med. Chem.* 34 (2000) 743–750, doi:10.1016/S0223-5234(00)00157-4.
- [14] E.M. Grivaky, S. Lee, C.W. Siyal, D.S. Duch, C.A. Nichol, Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-*d*]pyrimidine, *J. Med. Chem.* 23 (1980) 327–329, doi:10.1021/jm00177a025.
- [15] J.I. DeGraw, P.H. Christie, W.T. Clowell, F.M. Sirotnak, Synthesis and antifolate properties of 5,10-ethano-5,10-dideazaaminopterin, *J. Med. Chem.* 35 (1992) 320–324, doi:10.1021/jm00080a017.
- [16] S. Furuya, T. Ohtaki, *Pyridopyrimidine derivatives, their production and use*, *Eur. Pat. Appl. EP.* (1994) 608565.

- [17] D. Heber, C. Heers, U. Ravens, Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyridido[2,3-d]pyrimidine-2,4-dione in cardiac muscle from guinea-pig and man. part 6: compounds with positive inotropic activity, *Pharmazie* 48 (1993) 537–541.
- [18] A.A. Elfiky, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19, *Life Sci.* 248 (2020) 1174477, doi:10.1016/j.lfs.2020.117477.
- [19] G.Sh. Khan, A. Shah, Zia-ur Rehman, D. Barker, Chemistry of DNA minor groove binding agents, *J. Photochem. Photobiol. B* 115 (2012) 105–118, doi:10.1016/j.jphotobiol.2012.07.003.
- [20] S. Holguin, J. Martinez, C. Chow, R. Wurtman, Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils, *FASEB J.* 22 (2008) 3938–3946, doi:10.1096/fj.08-112425.
- [21] A.A. Rezaabakhsh, S.H. Khodaei, Novel coronavirus (COVID-19): a new emerging pandemic threat, *J. Res. Clin. Med.* 8 (2020) 5, doi:10.34172/jrcm.2020.005.
- [22] S.S. Shinde, G. Rashinkar, R. Salunkhe, DABCO entrapped in agar-agar: a heterogeneous gelly catalyst for multi-component synthesis of 2-amino-4H-chromenes, *J. Mol. Liq.* 178 (2013) 122–126, doi:10.1016/j.molliq.2012.10.019.
- [23] B.P. Bandgar, L.S. Uppalla, Gel entrapped base catalysed (GEB) henry reaction: synthesis of conjugated nitroalkenes, *Synth. Commun.* 30 (2000) 2071–2075, doi:10.1080/0039791000807384.
- [24] F. Shirini, M.S.N. Langarudi, M. Seddighi, O.G. Jolodar, Bi-SO₃H functionalized ionic liquid based on DABCO as a mild and efficient catalyst for the synthesis of 1,8-dioxo-octahydro-xanthene and 5-arylmethylene-pyrimidine-2,4,6-trione derivatives, *Res. Chem. Intermed.* 41 (2015) 8483–8497, doi:10.1007/s11164-014-1905-1.
- [25] F. Shirini, M.S.N. Langarudi, N. Daneshvar, N. Jamasbi, M. Irankhah-Khanghah, Preparation and characterization of [H₂-DABCO][ClO₄]₂ as a new member of DABCO-based ionic liquids for the synthesis of pyrimido[4,5-b]quinoline and pyrimido[4,5-d]pyrimidine derivatives, *J. Mol. Struct.* 1161 (2018) 366–382, doi:10.1016/j.molstruc.2018.02.069.
- [26] V.V. Lipson, S.M. Desenko, M. G. Shirobokova, V.V. Borodina, Synthesis of 9-Aryl-6,6-dimethyl-5,6,7,9-tetrahydro-1,2,4-triazolo[5,1-b]quinazolin-8(4H)ones, *Chem. Heterocycl. Compd.* 39 (2003) 1213–1217 <https://doi.org/10.1023%2FB%3ACOHC.0000008269.69460.ac>.
- [27] M.M. Heravi, F. Derikvand, L. Ranjbar, Sulfamic acid-catalyzed, three-component, one-pot synthesis of [1,2,4]triazolo/benzimidazolo quinazolinone derivatives, *Synth. Commun.* 40 (2010) 677–685, doi:10.1080/00397910903009489.
- [28] N. Seyyedi, F. Shirini, M.S.N. Langarudi, S. Jashnani, A simple and convenient synthesis of [1,2,4]triazolo/benzimidazolo quinazolinone and [1,2,4]triazolo[1,5-a]pyrimidine derivatives catalyzed by DABCO-based ionic liquids, *J. Iran. Chem. Soc.* 14 (2017) 1859–1867 <https://doi.org/10.1007%2Fs13738-017-1125-x>.
- [29] M.M. Heravi, L. Ranjbar, F. Derikvand, B. Alimadadi, H.A. Oskooie, F.F. Bamoharram, A three component one-pot procedure for the synthesis of [1,2,4]triazolo/benzimidazolo-quinazolinone derivatives in the presence of H₆P₂W₁₈O₆₂•18H₂O as a green and reusable catalyst, *Mol. Divers.* 12 (2008) 181–185 <https://doi.org/10.1007%2Fs11030-008-9086-8>.
- [30] R.G. Puligoundla, Sh. Karnakanti, R. Bantu, N. Kommu, S.B. Kondra, L. Nagarapu, A simple, convenient one-pot synthesis of [1,2,4]triazolo/benzimidazolo quinazolinone derivatives by using molecular iodine, *Tetrahedron Lett.* 54 (2013) 2480–2483, doi:10.1016/j.tetlet.2013.02.099.
- [31] A. Shaabani, E. Farhangi, A. Rahmati, Synthesis of tetrahydrobenzimidazo[1,2-b]quinazolin-1(2H)-one and tetrahydro-1,2,4-triazolo[5,1-b]quinazolin-8(4H)-one ring systems under solvent-free conditions, *Comb. Chem. High Throughput Screen.* 9 (2006) 771–776, doi:10.2174/138620706779026060.
- [32] K. Kumari, D.S. Raghuvanshi, K.N. Singh, An expeditious synthesis of tetrahydro-1,2,4-triazolo[5,1-b]quinazolin-8(4H)-ones and dihydro-1,2,4-triazolo[1,5-a]pyrimidines, *Org. Prep. Proced. Int.* 44 (2012) 460–466, doi:10.1080/00304948.2012.715062.
- [33] Shaabani A, E. Farhangi, Sh. Shaabani, A rapid combinatorial library synthesis of benzazolo[2,1-b]quinazolinones and triazolo[2,1-b]quinazolinones, *Iran. J. Chem. Chem. Eng.* 32 (2013) 3–10 http://www.ijcce.ac.ir/article_5899.html.
- [34] M. Haghighat, F. Shirini, M. Golshekan, Efficiency of NaHSO₄ modified periodic mesoporous organosilica magnetic nanoparticles as a new magnetically separable nanocatalyst in the synthesis of [1,2,4]triazolo quinazolinone/pyrimidine derivatives, *J. Mol. Struct.* 1171 (2018) 168–178, doi:10.1016/j.molstruc.2018.05.112.
- [35] K. Ablajan, W. Kamil, A. Tuoheti, S. Wan-Fu, An efficient three component one-pot synthesis of 5-amino-7-aryl-7,8-dihydro-[1,2,4] triazolo[4,3-a]pyrimidine-6-carbonitriles, *Molecules* 17 (2012) 1860–1869, doi:10.3390/molecules17021860.
- [36] N. Jamasbi, M. Irankhah-Khanghah, F. Shirini, H. Tajik, M.S.N. Langarudi, DABCO-based ionic liquids: introduction of two metal-free catalysts for one-pot synthesis of 1,2,4-triazolo[4,3-a]pyrimidines and pyrido[2,3-d]pyrimidines, *New J. Chem.* 42 (2018) 9016–9027, doi:10.1039/C8NJ01455H.
- [37] S.C. Azimi, Cellulose sulfuric acid catalyzed multicomponent reaction for efficient synthesis of pyrimido and pyrazolo[4,5-b]quinolines under solvent-free conditions, *Iran. J. Catal.* 2 (2014) 113–120 http://ijc.iaush.ac.ir/article_552171.html.
- [38] D.Q. Shi, S.N. Ni, F. Yang, J.W. Shi, G.L. Dou, X.Y. Li, X. Sh. Wang, S.J.J. Ji, An efficient synthesis of pyrimido[4,5-b]quinoline and indeno[2',1':5,6]pyrido[2,3-d]pyrimidine derivatives via multicomponent reactions in ionic liquid, *Heterocycl. Chem.* 45 (2008) 693–702, doi:10.1002/jhet.5570450310.
- [39] K. Mohammadi, F. Shirini, A. Yahyamdeh, 1, 3-Disulfonic acid imidazolium hydrogen sulfate: a reusable and efficient ionic liquid for the one-pot multicomponent synthesis of pyrimido [4, 5-b] quinoline derivatives, *RSC Adv.* 5 (2015) 23586–23590, doi:10.1039/C5RA02198G.
- [40] S. Abdolmohammadi, S. Balalae, An efficient synthesis of pyrido[2,3-d]pyrimidine derivatives via one-pot three-component reaction in aqueous media, *Int. J. Org. Chem.* 2 (2012) 7–14, doi:10.4236/ijoc.2012.21002.
- [41] A. Mossafai-Rad, M. Mokhtary, Efficient one-pot synthesis of pyrido[2,3-d]pyrimidines catalyzed by nanocrystalline MgO in water, *Int. Nano. Lett.* 5 (2015) 109–123, doi:10.1007/s40089-015-0145-8.
- [42] D. Shi, Sh. Ji, L. Niu, J. Shi, X. Wang, One-pot synthesis of pyrido[2,3-d]pyrimidines via efficient three-component reaction in aqueous media, *J. Heterocycl. Chem.* 44 (2007) 1083–1090, doi:10.1002/jhet.5570440517.
- [43] O.G. Jolodar, F. Shirini, M. Seddighi, Efficient synthesis of pyrano[2,3-d]pyrimidinone and pyrido[2,3-d]pyrimidine derivatives in presence of novel basic ionic liquid catalyst, *Chin. J. Catal.* 38 (2017) 1245–1251, doi:10.1016/S1872-2067(17)62827-4.
- [44] H. Alluri, H. Gonthina, R.K. Ganta, M. Ch, V. Rao, B. Efficient one-pot synthesis of multi-substituted triazolopyrimidines by using DBU as basic catalyst via MCR's, *Der. Pharma Chem.* 7 (2015) 515–520.
- [45] P. Bhattacharyya, S. Paul, A.R. Das, Facile synthesis of pyridopyrimidine and coumarin fused pyridine libraries over a Lewis base-surfactantcombined catalyst TEOA in aqueous medium, *RSC Adv.* 3 (2013) 3203–3208, doi:10.1039/c3ra23254a.
- [46] B. Sabour, M.H. Peyrovi, M. Hajimohammadi, Al-HMS-20 catalyzed synthesis of pyrano[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines via three-component reaction, *Res. Chem. Intermed.* 41 (2015) 1343–1350, doi:10.1007/s11164-013-1277-y.